#94 - Bug biosecurity, brain chips and eye-boosting botanicals
The coffee break biotech roundup, by SomX.
Hello, my entomology enthusiasts,
This week, it’s a bug’s life as a creepy-crawly quarantine facility lands in York to shore up the UK’s biosecurity, saffron makes the leap from spice rack to retinal protection, Chiesi stings the US rare disease market with a $1.9bn acquisition, AstraZeneca warms back up to UK investment after a government sweetener, and a blueberry-sized brain implant buzzes into human trials for treatment-resistant depression.
Don’t let the bedbugs bite!
Dodo
If there’s anything you’d like to see in future editions of Biotech Dodo, send us a message.
Discover 🔍
🐜 Insect quarantine unit to be launched at York biotech campus (The Press): Our friends up north are boosting the UK’s biosecurity capabilities with a new state-of-the-art Insect Quarantine Unit for Fera Science Ltd. The facility will support research into invasive invertebrate pests – the sort that chew through crops, ecosystems and biosecurity budgets. The 2,500 sq ft unit is designed to handle the kind of regulated work that requires rather more than a sealed jar and good intentions, with serious implications for food systems and environmental protection.
Our take: The UK has made plenty of noise about leading in crop science, from the Precision Breeding Act to post-EU regulatory divergence. Fera Science's work with DEFRA on invasive non-native species is more than mere research curiosity – after all, you can't set policy on pests you haven't properly studied! York's expanded facility is the unglamorous plumbing behind the UK's biosecurity ambitions, and with 10 to 12 invasive species turning up uninvited each year, more capacity is rather overdue.
🥸 Pharmactive Biotech highlights saffron extract’s clinical efficacy in boosting vision health (Nutrition Insight): Pharmactive has launched AffronEye, a saffron-derived ingredient aimed at retinal protection through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. Preclinical data shows it shields retinal ganglion cells in glaucoma-like models, while delivery formats including liposomal lid mists and eyelid serums are designed to sidestep the compliance problems that plague traditional eye drops.
Our take: Pharmactive is betting that the future of eye wellness lies in ease of application. A natural botanical that feels more like skincare than medicine has clear appeal – in nutraceuticals, poor adherence is the silent killer of otherwise promising interventions, with many users dropping off after just a couple of weeks. Liposomal lid mists and eyelid serums directly address the friction points that make people disengage.
🤑 Chiesi in US$1.9bn deal to buy KalVista and its angioedema drug (European Biotechnology Magazine): Our pasta-loving pals at Chiesi are making their largest acquisition to date, snapping up US biotech KalVista Pharmaceuticals for $1.9bn. The centrepiece is Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema – a condition where existing options are largely injectable. Ekterly has already secured regulatory approval in the US, UK, Japan and EU, generating $49M in its first half-year on market.
Our take: KalVista is Chiesi’s second significant rare disease deal in three years, following the Amryt Pharma buyout in 2023 – with a €430M Milan manufacturing investment and an Arbor gene therapy partnership added for good measure. The methodical deal-making is worth noting: a family-owned company quietly assembling US commercial-stage assets while anchoring its manufacturing base at home, all in service of a €6bn revenue target by 2030.
🇬🇧 AstraZeneca makes surprise U-turn with £300m pharma investment in UK (The Guardian): AstraZeneca has reversed its UK investment freeze, unfreezing a paused £200m Cambridge expansion and committing £100m to a new “lab of the future” in Macclesfield. The U-turn follows months of fractious negotiations over NHS drug pricing and availability. A subsequent UK–US deal, trading tariff-free exports for improved NHS medicine access, appears to have broken the deadlock.
Our take: Since the UK–US pricing deal, £1.4bn in life sciences investment has rolled in from UCB, Bristol Myers Squibb, Boehringer Ingelheim and now AstraZeneca. The terms were straightforward enough: higher NHS drug spending and faster approvals in exchange for investment commitments. Whether this becomes the standard playbook – governments competing for pharma capital by loosening pricing and access conditions – is the rather larger question.
And finally…
🧠 A brain implant for depression is about to be tested in humans (Wired): Motif Neurotech has FDA approval to begin human trials of a blueberry-sized brain implant for treatment-resistant depression. The device targets the central executive network with frequent at-home electrical stimulation, with the company suggesting remission could be achievable within 10 days. Unlike Neuralink’s headline-grabbing communication-restoration work, Motif is aiming squarely at the third of depression patients who don’t respond to existing medication.
Our take: Treatment-resistant depression is a condition that current psychiatry has remarkably little to offer beyond palliation, and a device-based intervention is a meaningful shift. The longer-term implication is that recording-and-stimulating implants could move psychiatric diagnosis from patient self-report to neural telemetry – a significant epistemological change for a field built on subjective accounts, with real consequences for how depression is defined and treated.
Tune in 🎧
🫀 Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases: Diagonal Therapeutics’ CSO Patrick Andre explains how the DIAGONAL platform targets TGF-β signalling, and what a $125M Series B means for rare vasculopathies and beyond.
💡 Implementing a new CEO strategy with NervGen’s Adam Rogers, M.D. and Rich Macary: NervGen's Adam Rogers and Rich Macary discuss NVG-291's path to Phase 3, FDA endpoint strategy, leadership shifts, a Nasdaq move, and the broader potential in neurotrauma.
🥶 The first environmental GE organism release – almost! Dr. Steven Lindow: Dr. Steven Lindow unpacks the pioneering work on ice-minus bacteria, early biotech breakthroughs, regulatory hurdles, and the technology’s evolving role in frost-sensitive agriculture.
Apply ✍️
🤖 Business Lead, Life Sciences, OpenAI: Want to turn complex life sciences workflows into transformative partnerships? You'll manage a portfolio of strategic accounts, define market and buyer narratives, and translate deep scientific insight into commercial pathways.
🧑🔬 Manager, Life Sciences Strategy Consulting, Kx Advisors: Interested in running multiple client engagements while growing a team of consultants? You'll lead end-to-end project delivery, support business development, serve as a strategic thought partner, and connect teams, clients, and senior leadership.
🌍 Global Change Facilitator, BioPhorum: Passionate about turning cross-industry collaboration into real-world impact? You'll lead workstreams of senior biopharma experts, facilitate complex discussions, drive industry-shaping guidance and benchmarks, and combine structured thinking with project leadership.
RSVP 📆
🦠11–15.05 | PEGS Boston | Boston, USA: A flagship conference for protein and antibody engineering, immunotherapy, and AI-driven biologics – showcasing the tools and partnerships transforming drug discovery and development.
🚧 13.05 | Cybersecurity and clinical risk management in the era of AI | Royal Society of Medicine, London, UK: A half-day event for clinicians, healthcare leaders, and digital health professionals navigating AI's security and clinical risks, with practical guidance from NHS CCIOs on deploying it safely and compliantly.
🔬19–21.05 | Bio-IT World Conference & Expo | Boston, USA: A 25-year-old flagship for biopharma, clinical research, and tech leaders – spotlighting informatics, data analytics, and AI-driven tools accelerating precision medicine and drug discovery.
Got news, jobs or events you think are worth coo-ing over? Post an event here, or email us at biotechdodo@substack.com!
We’re SomX – a communications and creative agency trusted by biotech, pharma and healthtech pioneers. We craft strategy, content, PR and design that translate complex biology into compelling stories and investor‑ready excitement. Get in touch to amplify your science beyond the lab bench.